Axe Compute (AGPU) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
14 Aug, 2026Executive summary
Focus shifted to providing high-performance GPU compute infrastructure for AI workloads, with legacy drug discovery business now non-core and under strategic review.
Major new contracts signed, including a $260M, 36-month enterprise infrastructure agreement and three additional contracts in July 2026 totaling over $2.8B.
Strategic treasury management centers on ATH tokens, used to secure GPU capacity and as a liquidity reserve.
Financial highlights
Revenue for the six months ended June 30, 2026 was $3.3M, up from $0.1M year-over-year, driven by Compute Services.
Net loss for the six months ended June 30, 2026 was $24.9M, compared to $4.5M in the prior year period.
Losses on digital assets (ATH) totaled $17.4M for the six months ended June 30, 2026.
Cash and cash equivalents at June 30, 2026 were $21.9M, up from $10.8M at year-end 2025.
Accumulated deficit increased to $438.4M from $413.5M at December 31, 2025.
Outlook and guidance
Company expects continued operating losses in the near term as it scales compute and treasury initiatives.
Liquidity is supported by cash, ATH holdings, and $83M available under an ATM equity facility.
Management believes current liquidity sources are sufficient for at least the next twelve months.
Latest events from Axe Compute
- Offering up to $1B in securities to scale AI-focused GPU infrastructure and digital asset reserves.AGPU
Registration filing - AI compute infrastructure provider seeks up to $1B for growth, leveraging ATH token reserves.AGPU
Registration filing - AI infrastructure provider seeks to raise $1B for GPU expansion and strategic reserves.AGPU
Registration filing - $260M contract and $4.3B pipeline drive AI compute pivot; Q1 net loss $7.7M, revenue $35K.AGPU
Q1 2026 - Raised $343.5M, secured $12M in contracts, and ended 2025 with a $233M net loss.AGPU
Q4 2025 - Registering 1.98M shares for resale; proceeds from warrant exercises fund operations.AGPU
Registration Filing - AI-driven oncology firm shifts capital to Aethir tokens, heightening volatility and regulatory risk.AGPU
Registration Filing - AI oncology and ATH-focused treasury strategy drive growth amid high digital asset risk.AGPU
Registration Filing - Q2 2024 saw a $3.2M loss, cost cuts, and new AI/ML partnerships amid going concern risks.AGPU
Q2 2024